Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Product Portfolio
INCY logo

Incyte's Net Income Soars 75% to $597.6M, Driven by JAKAFI and OPZELURA Growth

INCY10-KFiling Date: 2/13/2024
Incyte Corporation
Description

What this story covers

Incyte Corp's 2023 10-K reveals a 75 percent net income surge to 597 point 6 million dollars, fueled by JAKAFI and remarkable OPZELURA sales growth. The biopharma company, strong in oncology and dermatology, maintains a robust pipeline and liquidity despite patent expiry and regulatory risks.

Story snapshot

CompanyIncyte Corporation
TickerINCY
VariantStandard detailed
Duration35:28
Filing type10-K
PeriodAnnual 2023
IndustryHealthcare & Pharmaceuticals
Accession0000879169-24-000045

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in